Invasive infections (e.g.,
bloodstream infections) caused
by CRE have been associated with
high mortality rates (up to 40
to 50% in some studies).
• In addition to β-lactam/
carbapenem resistance, CRE
often carry genes that confer high
levels of resistance to many other
antimicrobials, often leaving very
limited therapeutic options. “Panresistant”
CRE have been reported.
• CRE have spread throughout
most parts of the United States
and other countries and have the
potential to spread more widely.
• Currently in the United States,
CRE are primarily identified
among patients with healthcare
exposure, but there is potential
for CRE to spread outside of
healthcare settings, given that
Enterobacteriaceae are a common
cause of community-associated
infections.